Compliance with treatment: related-issues and insights for pharmacist intervention by Silva, Nilcéia Lopes da et al.
*Correspondence: N. L. Silva. Departamento de Farmácia, Faculdade 
de Ciências Farmacêuticas, Universidade de São Paulo. Av. Prof. Lineu 
Prestes, 580, Bloco 15, 05508-900 - São Paulo - SP, Brasil. E-mail: 
nilceias@yahoo.com
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 47, n. 1, jan./mar., 2011
Compliance with treatment: related-issues and insights for 
pharmacist intervention
Nilcéia Lopes da Silva1,2*, Eliane Ribeiro1, João Luis Navarro2, Antonio Carlos Zanini1
1Department of Pharmacy, College of Pharmaceutical Sciences, University of São Paulo, São Paulo,  
2Novartis Biociências S.A., Brazil
Low patient compliance with pharmacotherapy remains one of the greatest challenges for success of 
treatments, especially in chronic diseases, since it can negatively influence treatment effectiveness and 
patient quality of life, increase health expenses and decrease productivity of the patient. Compliance is 
an important but complex issue in clinical practice. Its complexity begins with the difficulty in adopting 
terminology that can express its exact meaning. Moreover, many methods to evaluate compliance have 
been established but no consensus exists on which method should be considered the gold standard. 
Additionally, socioeconomic, disease and therapy-related factors, healthcare team and system related-
factors and patient-related factors can simultaneously influence compliance levels. In this highly 
complex scenario, pharmacist interventions have been identified as an effective strategy to enhance 
patient compliance with treatment. The objectives of this paper were: (1) to provide useful information 
for pharmacists about issues related to compliance such as terminology and definitions; methods for 
measuring compliance and persistence; influencing factors and the impact of low compliance; and (2) 
to offer insight into how these healthcare professionals can effectively contribute toward improved 
compliance levels.
Uniterms: Pharmacotherapy/compliance with treatment. Medicines/use. Chronic diseases/therapy. 
Pharmacists/interventions.
A baixa adesão dos pacientes ao tratamento medicamentoso de doenças crônicas continua sendo um 
dos maiores desafios da medicina, por comprometer a efetividade do tratamento, repercutindo na 
qualidade de vida, aumentando os gastos com saúde e diminuindo a produtividade do indivíduo doente. 
O tema adesão é tão relevante para a prática clínica quanto complexo, a começar pelas tentativas de 
adoção de uma terminologia que expresse com exatidão o seu significado. Além disso, vários métodos 
para sua determinação foram estabelecidos sem, contudo, se chegar a um consenso sobre qual seria o 
“ótimo”. Adicionalmente, as condições socioeconômicas, as características da doença, os tratamentos 
empregados, o sistema de saúde e seus profissionais ou o próprio paciente são alguns dos distintos 
fatores que influenciam, simultaneamente, o nível de adesão do paciente ao tratamento. Neste cenário 
de alta complexidade, intervenções realizadas pelo profissional farmacêutico têm sido apontadas como 
estratégias efetivas para o aumento dos níveis de adesão do paciente ao tratamento. Os objetivos deste 
artigo são: (1) fornecer aos farmacêuticos algumas informacões úteis relacionadas ao assunto adesão 
tais como: terminologia e definições, métodos para medir adesão e persistência, fatores influenciadores 
e impacto da baixa adesão; (2) fornecer algumas idéias a respeito de como estes profissionais de saúde 
podem efetivamente contribuir para a melhora dos níveis de adesão.
Unitermos: Tratamento medicamentoso/adesão. Medicamentos/uso. Doenças crônicas/tratamento. 
Farmacêutico /intervenções.
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INTRODUCTION
Cardiovascular diseases are the main cause of mor-
tality in Brazil and account for about 30% of all causes of 
death (Brasil. Ministério da Saúde, 2008). In spite of the 
many available drugs for these conditions that provide 
efficacy in reducing morbidity and mortality, low patient 
compliance with treatment remains one of the greatest 
challenges in routine clinical practice (Wu et al., 2006).
There is no consensus on the level of compliance 
considered to be adequate (Osterberg, Blaschke, 2005). 
Rates of compliance vary widely in the literature even in 
controlled clinical trials (Kenreigh, Wagner, 2005). The 
rate of compliance can also vary according to type of study, 
patient population, method of data collection and techni-
que used to measure compliance (Muszbek et al., 2008).
According to the World Health Organization, rates 
of compliance with antihypertensive agents range from 
50% to 70%, while 16% to 50% of patients give up their 
treatments within the first year (World Health Organiza-
tion, 2003).
Regarding antilipemic agents, it is estimated that 
only 50% of patients who are being treated with statins 
continue to use their medication after six months, and 
only 30% to 40% after one year (American Heart Asso-
ciation, 2002).
In studies assessing the cost-consequences of non-
compliance, compliance rates were 45-80% in diabetes, 
15-35% in hypertension, 31-59% in hypercholesterolemia 
and 60-96% in other diseases such as heart failure and 
coronary heart diseases (Muszbek et al., 2008).
Reviews of compliance-enhancing interventions 
sug gest that many educational and behavioral inter-
ventions are efficacious, especially those conducted by 
pharmacists. However, practitioners generally lack formal 
training on these techniques (Svarstad et al., 2009).
The objectives of this paper were to provide use-
ful information for pharmacists about issues related to 
compliance and to offer insight into how these healthcare 
professionals can effectively contribute toward improving 
compliance levels.
TERMINOLOGY AND DEFINITIONS
Many terms have been found in the literature as sy-
nonyms for compliance such as adherence, concordance, 
fidelity, obedience and observance (Zanini, Paulo, 1997; 
Wahl et al., 2005; Gusmão, Mion Jr., 2006).
At the end of the 1970’s, “compliance” was defined 
as the level of extent to which a person’s behavior (in 
terms of taking medications, following diet regimens or 
executing life style changes) coincides with medical or 
health advice (Lutfey, Wishner, 1999).
This definition reflects how health professionals 
at the time, perceived the physician-patient relationship: 
patients had to obey physician’s instructions, demonstra-
ting a kind of paternalistic behavior (Strömberg, 2006). 
However, Zanini and Paulo (1997) had previously called 
attention to the fact that treatment effectiveness also de-
pends on patient trust in the physician: patient feelings of 
respect and admiration for the physician could encourage 
him/her to better tolerate adverse effects of drugs whereas 
no trust, or lack of credibility in physician’s recommen-
dations could lead patients to worrying excessively about 
their health and adverse effects of drugs, resulting in 
noncompliance with drug treatment (Zanini, Paulo, 1997).
Advances in knowledge about the determinants of 
human behavior for health has highlighted the fact that the 
patient needs to be seen as a person who actively influen-
ces their treatment through their beliefs, willingness and 
attitudes (Tourette-Turgis, Rebillon, Pereira-Paulo, 2005).
In 1995, the Royal Pharmaceutical Society of Great 
Britain (RPSGB) performed a study to better understand 
patients’ difficulties in following prescribed drug treatment 
(Royal Pharmaceutical Society, 1997). After this research, 
at the end of the 1990’s, the term “concordance” started 
to be used in Great Britain to describe the new way that 
physicians handled patient consultations: empowering 
patients to achieve effective treatment (Hobden, 2006).
At the same time, in the Anglo-Saxon literature, 
the term “adherence” replaced the term “compliance” 
meaning approval, consent, or concordance. This term 
suggests that the patient assumes a more active role in 
issues regarding their health: defining and pursuing goals 
for the treatment of their disease (Osterberg, Blaschke, 
2005; Tourette-Turgis, Rebillon, Pereira-Paulo, 2005).
Thus, interactions with patients should not be 
viewed simply as opportunities for reinforcing instructions 
centered on treatment, but rather, they should be seen as 
a space where the expertise of patients and health profes-
sionals can be pooled to arrive at mutually agreed goals 
(Bissel, May, Noyce, 2004).
Although adherence is the word preferred by many 
healthcare providers, both terms, “adherence” and “com-
pliance” are imperfect and uninformative descriptions of 
medication-taking behavior (Osterberg, Blaschke, 2005).
According to the World Health Organization, pa-
tient compliance with treatment is defined as the extent to 
which a person’s behavior – taking medication, following 
a diet and/or executing lifestyles changes – corresponds 
with agreed recommendations from healthcare providers 
(World Health Organization, 2003).
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Regarding the use of medicines, a person’s behavior 
can be analyzed from two slightly different aspects: (1) 
taking medications at the prescribed frequency / interval 
and dose / dosing regimen and (2) continuing their use for 
the specified treatment time period (Halpern et al., 2006). 
For each of these components of patient compliance with 
drug treatment, two specific terms are adopted, namely, 
compliance (or adherence) and persistence, respectively.
With the objective of enabling comparisons among 
compliance studies, the International Society of Pharma-
coeconomics and Outcomes Research (ISPOR) suggested 
the standardization of compliance and persistence defini-
tions as follows (Cramer et al., 2008a):
1. Medication compliance (synonym: adherence) 
refers to the act of conforming to the recommendations 
made by the healthcare provider with respect to timing, 
dosage and frequency of medication taking. Adherence is 
measured over a period of time and reported as a percen-
tage of doses taken as prescribed.
2. Medication persistence is defined as “the duration 
of time from initiation to discontinuation of therapy”. 
Continuing to take any amount of the medication is con-
sistent with the definition of persistence. By definition, 
persistence is reported as a continuous variable in terms 
of number of days for which therapy was available. It may 
also be reported as a dichotomous variable measured at 
the end of a predefined time period, considering patients 
as being ‘persistent’ or ‘nonpersistent’.
METHODS FOR MEASURING COMPLIANCE
The available methods for measuring compliance 
with drug treatment can be classified into direct and indi-
rect methods. Each method has advantages and disadvan-
tages but there is no consensus on which method can be 
considered the gold standard (Osterberg, Blaschke, 2005). 
Direct methods seek to confirm whether there was 
ingestion of medicines by the patient, while in the indirect 
methods there is no confirmation as to whether the patient 
had taken the medicine (Oigman, 2006).
There are three direct methods: (1) directly observed 
therapy; (2) measurement of the level of medicines or 
metabolites in blood or urine; (3) measurement of biolo-
gical markers in blood (World Health Organization, 2003; 
Osterberg, Blaschke, 2005; Oigman, 2006).
In the directly observed therapy, the medicine is offe-
red to the patient by a healthcare professional that witnesses 
medicine ingestion by the patient. Although this is the most 
accurate method, patients can potentially hide pills in their 
mouth and discard them later. Additionally, the method is 
impractical for routine use (Osterberg, Blaschke, 2005).
Measurements of concentrations of a drug or its 
metabolite in blood or urine constitute another direct me-
thod. However, variations in metabolism can give a false 
impression of compliance with drug treatment (World He-
alth Organization, 2003). Another important consideration 
is that a patient who exceptionally takes the prescribed 
medicine only immediately before collection of biological 
material for laboratorial analysis, could be classified as 
compliant while a patient who takes the medicine regularly 
but has interrupted the treatment in the last 24 or 48 hours 
before biological material collection could be classified as 
noncompliant. In spite of these drawbacks, it is considered 
a reliable method (Rocha Jr., 1997).
Finally, in the measurement of biological markers 
in blood, an innocuous substance is added to the drug 
formulation and measurements of concentrations of this 
marker in blood are subsequently performed. This method 
implies the handling of the medicines and this raises some 
ethical aspects (Rocha Jr., 1997; Oigman, 2006). Additio-
nally, the method calls for expensive quantitative assays 
and collection of body fluids (Osterberg, Blaschke, 2005). 
Therefore, it is considered an expensive method, available 
for a limited number of medicines that is both inconvenient 
to patients and impractical for routine use (Oigman, 2006; 
Mori et al., 2008).
Indirect evaluations of compliance can be performed 
by several methods: (1) assessing clinical response; (2) 
performing pill counts; (3) using electronic monitors; (4) 
ascertaining rates of refilling of prescription; (5) collecting 
information from healthcare professionals or from patients 
(World Health Organization, 2003; Osterberg, Blaschke, 
2005; Oigman, 2006; Gusmão et al., 2009).
Assessing clinical response has been considered 
the simplest method which is generally easy to execute. It 
assumes that clinical response is a variable that depends 
only on adherence, and does not consider the possibility 
that other factors influence this clinical response (Oigman, 
2006). However, health problems can sometimes be solved 
or controlled by factors other than adherence (Delgado, 
Lima, 2001). Further, patients can show good adherence 
and yet may not necessarily present the desired clinical 
response. Clinical response can be used as measurement 
of drug adherence when the treatment is associated with 
a specific result, for example glycemic or blood pressure 
levels. However, some authors consider the occurrence 
of the “toothbrush effect”, i.e., the patient is compliant 
only immediately before visiting the doctor (Delgado, 
Lima, 2001). 
 In the counting of pills method, the compliance rate 
is determined by the difference between the number of 
pills acquired by the patient and the number of pills remai-
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ning in the box during a specified time period. Although 
simple, this approach has the disadvantage of being useful 
only for solid medicines and it is not possible to know 
whether the patient has ingested the correct amount of 
medicine per day or whether they have ingested the correct 
daily amount for fewer days (Rocha Jr., 1997).
Regarding electronic monitors such as Medications 
Events Monitoring System (MEMS), medication dosage 
units (pills, drops, etc) are separately placed in vials fitted 
with an electronic processor that can record the precise 
moment in which the vial is opened. This method assumes 
that each opening of the vial corresponds to an ingestion 
of medication (Osterberg, Blaschke, 2005; Oigman, 2006) 
and provides detailed information to calculate the number 
of doses taken daily at appropriate intervals, for instance 
approximately 12 hours for a twice-daily dosing regimen. 
Additional details can also be obtained such as number of 
days with extra doses or with no dose (Cramer, 2004). It is 
an expensive method and the majority of monitors are use-
ful only for solid formulations. As in the counting of pills 
method, results can be overestimated (Rocha Jr., 1997).
Measuring compliance by ascertaining rates of 
refilling of prescriptions requires a closed pharmacy 
system which provides information for the Medication 
Possession Ratio (MPR) calculation. When a person has 
their prescription filled out by a pharmacy included in this 
integrated system, the prescription data and the amount of 
medication delivered to the patient are registered (Oigman, 
2006; Halpern et al., 2006).
The MPR is defined as the sum of the days’ supply 
of medication divided by the number of days between the 
first fill and the last refill, plus the days’ supply of the last 
refill (Sikka, Xia, Aubert, 2005). Figure 1 exemplifies the 
MPR calculation.
An MPR of 1.0 indicates full (100%) compliance. 
MPR < 1 indicates lapses in prescription refilling. MPR 
equal to 1.0 can indicate that the patient has refilled the 
prescription before their medication has run out or has 
hoarded medication for later use. This value can be capped 
at 1.0 if it is unlikely that the patient has used a greater 
amount of medicine than that prescribed (Halpern et al., 
2006). For patients receiving concomitant medications, 
MPR should be calculated for each medication separately, 
and the overall MPR taken as the average of the individual 
MPR. However, care should be taken since compliance 
can vary according to the medication being evaluated. The 
main limitation of this method is the assumption that the 
proportion of days covered by a prescription corresponds 
to the proportion of days of medication used. Additionally, 
there is a chance a patient has refilled the prescription at 
the correct time intervals yet has not taken their medica-
tion according to the physician’s recommendations. Other 
limitations are related to the nature of databases, i.e. a 
patient may have acquired their medication from sources 
for which data are not captured, such as drug samples, 
from friends or family members or from pharmacies whi-
ch are not included in the integrated system for capturing 
electronic data (Halpern et al., 2006).
Indirect evaluation can also be carried out by col-
lecting information from healthcare professionals or from 
patients (patient self-reported assessment). This method is 
commonly used (Osterberg, Blaschke, 2005) being consi-
dered easy to apply and inexpensive, especially compared 
with the use of electronic monitors, biologic analyses 
or determining rates of refill of prescriptions (Kripalani 
et al., 2009). Nevertheless, indirect evaluation involves 
some degree of subjectivity (World Health Organization, 
2003). Patient self-reported assessment presents varying 
levels of concordance with other methods due to the use of 
different instruments for collecting data and administration 
techniques (Kripalani et al., 2009).
As a final point, patient information can be collected 
using different instruments such as patient diaries, struc-
tured questionnaires, questionnaires with scales, through 
interviews or simple reports (Oigman, 2006; Mori et al., 
2008; Kripalani et al., 2009). Among these instruments, 
the questionnaire incorporating a scale developed by Mo-
risky and colleagues (1986), the Morisky-Green Scale, has 
been in use for approximately 20 years (Kripalani et al., 
2009). It was originally developed for evaluating patient 
behavior patterns associated with the use of antihyperten-
sive drugs and consists of four-items with yes/no answer 
format, on a scale from 0 to 4. Each “yes” scores 0 (zero) 
Day count
Refilling 
process
Days’ supply 
of medication
Day 1 1st refill 30
From day 31 to day 45 No refill 0
Day 46 2nd refill 30
From day 76 to day 90 No refill 0
Day 91 3rd refill 30
From day 121 to day 130 No refill 0
Day 131 4th refill 30
From day 161 to day 335 No refill 0
Day 336 5th refill 30
Total number of days - 150
MPR (Medication Possession Ratio) = 150/365 = 0.41 or 41%
FIGURE 1 - MPR Calculation. Based on Sikka and colleagues 
(2005).
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points and each “no” is worth 1 (one) point. According 
to the sum of points, the patient can be classified into the 
following levels of compliance: high (4 points), medium 
(2-3 points) and low (0-1 point). With this method, com-
pliance can also be analyzed as a dichotomous variable: 
perfect compliance [score = 4 points] and imperfect com-
pliance [score ≤ 4 points] (Morisky, Green, Levine, 1986). 
Regarding measurement of persistence, Sikka and 
colleagues (2005) identified three methods in their review 
of studies measuring refilling persistence: (1) persistence 
as a function of MPR; (2) as a function of medication pos-
session at a fixed point in time; and (3) as a gap between 
refills (Sikka, Xia, Aubert, 2005).
In the first method, persistence is defined as a MPR ≥ 
80%. MPR is used as a dichotomous variable, and patients 
with MPR ≥ 80% are considered to be persistent for drug 
treatment (Sikka, Xia, Aubert, 2005). Although there is 
no statistic rationale for this cut-off point (MPR ≥ 80%), 
it has been used in many studies (Cramer et al., 2008b).
It is important to note that the MPR alone is not 
sufficient to provide information about the consistency 
of prescription refilling for a specific time period (Sikka, 
Xia, Aubert, 2005). For instance, during a one-year period 
Patient A has acquired their medication for 30 days’ supply 
every other month. Patient B has acquired their medication 
for 30 days’ supply, in the first month. After first acquisi-
tion, Patient B has not acquired their medication for the 
proceeding six months and then carried on acquiring their 
medications for 30 days’ supply every month for the rest of 
the one-year period. At the end of one-year period, Patients 
A and B will have the same MPR value. However, Patient 
A has shown a more consistent behavior pattern regarding 
refill of prescription compared with Patient B.
According to Sikka and colleagues (2005), this fact 
could be reasonable grounds for justifying the setting of 
an MPR value to greater than or equal to 80% to classify 
the patient as persistent or nonpersistent. The 80% cut-off 
suggests that the patient has gone only a few days without 
medication on hand and consequently could use this me-
dication regularly (Sikka, Xia, Aubert, 2005).
Evaluating persistence as a function of medication 
possession at a given point in time assumes that if the pa-
tient is in possession of medication on that specific data, 
then they are considered to have been persistent from the 
initial prescription up to this date. The timing and gaps 
between refills are not considered in this method. Let us 
take two patients (A and B) who have initiated their drug 
treatments in the first month of the year. Patient A acqui-
red their medication 12 times per year, every consecutive 
month and each time acquired sufficient medication for 30 
days’ supply. The last acquisition by Patient A was made 
at the beginning of month 12. Patient B acquired their 
medication 4 times per year, with intervals between each 
acquisition and each time acquired sufficient medication 
for 30 days´ supply. The last acquisition by Patient B was 
made at the beginning of month 12. Considering month 
12 was the date set for the evaluation, both patients will 
be considered to be persistent to drug treatment.
In the third method, persistence to drug treatment is 
evaluated as a function of gaps between refills. Each patient 
is given a certain grace period in which they can go without 
refilling prescription. Generally, this period is equal to half 
the number of days supplied with the filling of one prescrip-
tion. The grace period can also be calculated as a function 
of the number of days supplied with previous prescription 
refill, and can be equal to half or three times the number of 
days supplied with the previous filling. If the patient refills 
the prescription by the end of the grace period, they are 
considered persistent to drug treatment at that point in time, 
where persistence is measured in days. If the patient refill 
gap exceeds the determined grace period, then the patient 
is considered nonpersistent at that point in time.
The main advantage of this method compared with 
the other two is that it enables a profile of survival analy-
sis to be built and consequently allows the persistence of 
a specific population to drug treatment to be determined 
(Sikka, Xia, Aubert, 2005).
Figure 2 exemplifies how persistence can be measu-
red by these three different methodologies.
Finally, medication compliance can be evaluated 
through prospective and retrospective studies, both of 
which can provide data on the “real world”. However, 
participants in prospective studies cannot be compared 
with large populations and can introduce biases, especially 
those related to patient behaviors. Although the use of 
retrospective data does not introduce this kind of bias, the 
lack of consistent methods hampers comparison of results 
among studies (Halpern et al., 2006).
FACTORS THAT INFLUENCE COMPLIANCE
Numerous factors can simultaneously influence 
levels of compliance with treatment including those re-
lated to socioeconomic condition, disease and treatment 
characteristics, healthcare team and system and those 
factors related to patient characteristics (World Health 
Organization, 2003).
Factors such as gender, socioeconomic condition, 
race and marital status have not been consistently asso-
ciated with levels of compliance (Ockene et al., 2002; 
Osterberg, Blaschke, 2005). On the other hand, age has 
been reported as a factor that can influence compliance at 
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different times in life (Pan American Health Organization, 
2003). Poor compliance may be a way for young people 
to rebel against the treatment regimen’s control over their 
lives. Senior patients may not be compliant with treatment 
for a variety of reasons such as: memory or cognitive 
dysfunction; lack of understanding on the importance 
of medication or the recommendations regarding their 
disease treatment; inability to manage or to take multiple 
medicines; attitudes (refusal to follow healthcare profes-
sionals’ recommendations); beliefs (related to culture and 
spirituality); limited access to medications due to lack of 
transportation or money (Romano-Lieber et al., 2002; 
Murray et al., 2004). 
There is evidence that patient knowledge about their 
disease and treatment is a critical factor for encouraging 
them to actively participate in the decision-making pro-
cess related to their health (Golin et al., 1996). However, 
knowledge alone cannot be considered a guarantee of com-
pliance. Nevertheless, patients who have been educated by 
physicians or nurses and understand their disease process, 
the treatment goals, potential side effects associated with 
their medications, and the consequences of low complian-
ce, tend to be more compliant (Neutel, Smith, 2003). On 
the other hand, a study involving diabetic patients which 
sought to verify the relationship between compliance and 
patients’ knowledge about their disease revealed a dispa-
rity between what the patients were taught and what they 
were actually doing (Chan, Molassiotis, 1999).
Low compliance can be expected in the presen-
ce of chronic disease, in the absence or oscillation of 
symptoms, or even when the treatment is complex or 
includes life-style changes (Delamater, 2006). Levels of 
compliance are higher among patients with acute diseases 
compared to patients with chronic diseases, and persis-
tence among patients with chronic conditions is low, 
dropping most dramatically after the first six months of 
therapy (Osterberg, Blaschke, 2005). Patient perception 
of disease severity is associated with more elevated levels 
of compliance even if treatment lasts a long period of 
time (Leite, Vasconcelos, 2003). Comorbidities, drug and 
alcohol abuse can also negatively impact compliance/
persistence levels (Pan American Health Organization, 
2003). Some studies suggest that depression and anxiety 
have a detrimental influence on compliance, whereas 
others have failed to find this influence (Ockene et al., 
2002).
Limited financial means may lead patients to total 
or partial interruption of their treatments (World Health 
Organization, 2003; Sokol et al., 2005). However, low 
compliance is present even if medicines are freely dis-
tributed to patients but involve a complex therapeutic 
scheme and large number of prescribed medicines (Leite, 
Vasconcelos, 2003).
The effect of dosage frequency has been extensively 
studied and there is evidence that compliance with drug 
treatment decreases as the number of different medicines, 
number of pills and dosage frequency increases (Royal 
Pharmaceutical Society of Great Britain, 1997; Claxton, 
Cramer; Pierce, 2001). It has been demonstrated that pe-
ople are less likely to continue their medication regimen 
over long periods, and are less likely to be compliant with 
treatment when daily doses increase from 1 pill to 4 pills 
(Gottlieb, 2000). Results of a metanalysis showed that for 
antihypertensive medications, once daily dosing regimens 
Day count Refilling 
process
Days supply 
of medication
Days without 
medicine
Day 1 1st refill 30 0
From day 31 to 
day 45 
No refill 0 15
Day 46t 2nd refill 30 0
From day 76 to 
day 90
No refill 0 15
Day 91 3rd refill 30 0
From day 121 to 
day 130
No refill 0 10
Day 131 4th refill 30 0
From day 161 to 
day 335 
No refill 0 175
Day 336 5th refill 30 0
1. Persistence evaluated as a function of MPR
MPR (Medication Possession Ratio) = 150/365 = 0.41 or 41%
Patient is considered persistent to drug treatment if MPR ≥ 80%.
Result: not persistent
2. Persistence evaluated as a function of Medication Possession 
at a fixed point in time
Fixed point in time: Day 365.
Result: At the point in time fixed for evaluation, the patient has 
medication available so he/she is considered persistent to drug 
treatment from Day 1 to Day 365 or persistent at 1 year.
3. Persistence evaluated as a function of the gaps between refills
Grace period: 15 days.
Result: From Refill 4th , patient exceeds grace period. Thus , 
from this point in time he/she is considered to be nonpersistent 
to treatment. In other words, patient was persistent to drug 
treatment until Day 160.
FIGURE 2 - Evaluation of persistence to drug treatment using 
three different methodologies. Based on Sikka and colleagues 
(2005).
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are associated with higher rates of compliance than either 
twice-daily or multiple-daily dosing regimens (Iskedjian 
et al., 2002).
Many reasons have been cited to explain the in-
verse relationship between number of medicines that a 
patient has to take and their compliance with treatment, 
such as cost [greater cost associated with multiple drugs], 
convenience [easier to forget to take multiple drugs] and 
confusion [patients often become confused by multiple 
drugs and frequently dose them incorrectly] (Neutel, Smi-
th, 2003). Additionally, the occurrence of side effects has 
been associated with low compliance, especially in the tre-
atment of chronic diseases such as hypertension (Neutel, 
Smith, 2003; Burnier, 2006). All these factors, generally 
classified as therapy-related factors, are actually partially 
related to the patient’s decision on changing their life style 
or accepting some medication side effects (Leite, Vascon-
celos, 2003). Pathak and Thomas (2006) have shown that 
patients’ medication beliefs can also explain a significant 
portion of variation in medication noncompliance (Phatak, 
Thomas, 2006). Gatti and colleagues (2009) also verified 
that patients who had negative beliefs about medications 
had low compliance.
Finally, a positive supporting and trusting rela-
tionship between healthcare professional and patient im-
prove compliance with treatment (Krueger, Berger, Felkey, 
2005). Certain attitudes of healthcare professionals such 
as communication, time spent for consultation, friendly 
service, respect for patient needs and doubts, and encou-
raging patient to follow the agreed therapy, are important 
factors cited in the literature (Leite, Vasconcelos, 2003).
IMPACT OF LOW COMPLIANCE AND COM-
PLIANCE-ENHANCING STRATEGIES
Low compliance with treatment of chronic dise-
ases has a negative impact on effectiveness of therapy 
and is a critical factor in the health and quality of life of 
populations, as well as being an important factor from an 
economic perspective (Pan American Health Organization, 
2003).
In a study of survivors of acute myocardial infarction 
exploring the relationship between compliance with drug 
treatment and mortality, results showed that patients who 
had high levels of compliance with statins also had lower 
risk of mortality compared to those patients who had low 
compliance (Rasmussen, Chong, Alter, 2007).
Breekveldt-Postma and colleagues (2008) studied 
the effect of antihypertensive treatment discontinuation 
on risk of infarction and stroke in daily clinical practice. 
Of the 77,193 patients included, the percentage of nonper-
sistent patients was 55% at 2 years. Nonpersistence was 
associated with a 15% higher risk of acute myocardial 
infarction [RR 1.15; 95% CI 1.00-1.33] and a 28% higher 
risk of stroke [RR 1.28; 95% CI 1.15-1.45] (Breekvelt-
Postma et al., 2008).
In a retrospective cohort study that included 49,479 
chronic-medication treated patients, Bailey and colleagues 
(2010) verified that ambulatory visits and antihypertensive 
medication exposures were associated with reduced mor-
tality. Increasing compliance by one pill per week for a 
once-a-day regimen reduced the hazard of stroke by 8-9% 
and death by 7% (Bailey et al., 2010).
In fact, patients who presented high compliance 
with antihypertensive drugs were more likely to meet 
blood pressure goals (Bramley et al., 2006), their risk of 
cardiovascular events and hospitalization were decreased 
(Halpern et al., 2006) and they consumed less healthcare 
resources compared with patients who were not compliant 
with the prescribed treatment (Sokol et al., 2005)
The impact of compliance with treatment for 
diabetes, hypertension, hypercholesterolemia and heart 
failure on healthcare usage and costs was investigated 
in a retrospective study which included patients on a 
pharmacy benefit plan. For diabetes and hypercholeste-
rolemia, a high level of compliance with drug treatment 
was associated with lower disease-related medical costs. 
Under these conditions, higher medication costs were 
more than offset by medical cost reductions, producing 
a net reduction in overall healthcare costs. For all four 
studied conditions, hospitalization rates were significan-
tly lower for patients who had high compliance with drug 
treatment (Sokol et al., 2005).
Beyond direct costs, there are many other indirect 
costs related to noncompliance/nonpersistence such as 
absenteeism, loss of quality of life, loss of productivity, 
family problems, partial or total patient incapacity for self-
care and premature retirement (Lessa, 2006).
Among many initiatives focused on improving 
compliance with treatment, the multidisciplinary ap-
proach has been recognized as one of the most effective 
strategies (Osterberg; Blaschke, 2005; V Diretrizes Bra-
sileiras de Hipertensão Arterial, 2007). In a systematic 
review assessing the effectiveness of quality improve-
ment strategies in lowering blood pressure, Wash and 
colleagues (2006) suggested that a team change involving 
pharmacists may be one of the most effective quality 
improvement strategies for improving blood pressure 
control (Wash et al., 2006).
Glynn and colleagues (2010) reviewed all articles 
(any year) in the Cochrane Controlled Trial Register 
(CCTR) and on Medline and Embase from January 1980 
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onwards, to determine the effectiveness of interventions 
to improve control of blood pressure in patients with 
hypertension. The search yielded seventy-two randomized 
controlled trials (RCT’s) that met the inclusion criteria. 
Among all analyzed strategies, nurse and pharmacist-led 
care may be a promising way of improving control in 
patients with hypertension, with the majority of RCT’s 
being associated with improved blood pressure control, 
improved systolic blood pressure, and more modestly 
improved diastolic blood pressure (Glynn et al., 2010).
Svarstad and colleagues (2009) indicated five core 
compliance barriers that can be successfully addressed by 
pharmacists: regimen knowledge barriers [poor unders-
tanding of drug regimen and its elements such as dosage 
schedule treatment duration, purpose], recall barriers 
[difficulty remembering multiple drugs and doses], moti-
vational barriers [doubts regarding drug efficacy, benefits, 
or need therapy], side-effect barriers [bothersome side 
effects or concerns about long-term effects], and access 
barriers [difficulty affording or obtaining refills] (Svarstad 
et al., 2009).
Over recent years, many studies have emphasized 
the role of pharmacists in improving patient compliance 
levels. Smith and colleagues (1997) demonstrated that 
when there is a patient counseling by pharmacists before 
hospital discharge, patients’ level of compliance with treat-
ment tends to be higher compared to levels of compliance 
of patients who have not received pharmacists counseling 
(Smith et al., 1997). 
Wu and colleagues (2006) investigated the effecti-
veness of periodic telephone counseling by a pharmacist 
in reducing mortality in patients receiving polypharmacy. 
In this single-centre, randomized and controlled study, 
telephone counseling was associated with a 41% reduction 
in risk of death.
Lee and colleagues (2006) showed that levels of 
compliance with treatment can be improved after inter-
ventions performed during a pharmacy care program that 
included individualized medication education; medica-
tions dispensed using a compliance aid (blister packs) 
and regular follow-up with clinical pharmacists every 2 
months. After 8 months of interventions, the proportion of 
patients in whom all chronic medications were taken with 
a compliance rate of at least 80%, increased from 5.0% to 
98.7% (Lee, Grace, Taylor, 2006). 
In a retrospective analysis, Pindolia and colleagues 
(2009) evaluated the effectiveness of a medication therapy 
management program. In this program, clinical pharma-
cists, through telephone contact, ascertained patients’ he-
althcare goals and needs. Subsequently, a patient-centered 
pharmacotherapy plan was created and implemented 
collaboratively with the patient’s physician. Among the 
types of interventions performed by pharmacists, 60% 
involved changing therapy to improve efficacy and 40% 
involved changing therapy to improve safety. Additio-
nally, patients received counseling on medication and 
correlated diseases states. These interventions produced 
a trend toward improved compliance with drug therapy 
for heart failure, insulin use, to reduced pharmacy costs 
and sustained pharmacy cost savings for patients who en-
rolled in the program compared with those who declined 
enrollment.
Elliot and colleagues performed a study intervention 
assessing the cost effectiveness of pharmacists giving 
advice via telephone to patients receiving a new medicine 
for a chronic condition (Elliot et al., 2008). At 4-week 
follow-up, noncompliance was significantly lower in 
the intervention group (9% versus 16%; p = 0.032). The 
number of patients reporting medicine-related problems 
was significantly lower in the intervention group compared 
with the control group (23% versus 34%; p = 0.021) and 
there was a significant reduction in mean total patient costs 
at 2-month follow-up in the intervention group compared 
with the control group.
Kaboli and colleagues (2009) evaluated the pu-
blished literature on the effects of interventions by cli-
nical pharmacists on processes and outcomes of care in 
hospitalized adults. The reviewed studies showed that 
the introduction of clinical pharmacist services in the 
care of inpatients generally resulted in improved care. 
Pharmacist interactions with the healthcare team invol-
ved in patient rounds, interviewing patients, reconciling 
medications, providing patient discharge counseling and 
follow-up, all resulted in improved outcomes.
Duru and colleagues (2010) performed one of the 
first studies examining the characteristics of patients using 
mail-order pharmacies. Findings confirmed that patients 
who received newly prescribed medications through the 
mail were more likely to have good compliance than 
patients who obtained them from traditional pharmacies. 
Mail-order users had better compliance with antiglycemic, 
antihypertensive and lipid-lowering medications.
In Brazil, some initiatives have demonstrated the im-
portance of pharmacists in increasing patient compliance 
levels. One such initiative was the pharmacotherapy ma-
nagement program implemented by the Pharmacy Service 
of UNIMED, a Brazilian cooperative of physicians in 
Piracicaba, Sao Paulo State, between August 2006 and July 
2007 (Martins et al., 2007). In Porto Alegre, Rio Grande 
do Sul State, a double-blind randomized study, which 
enrolled 71 patients with uncontrolled blood pressure in 
a pharmaceutical care program, showed that pharmacists 
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can contribute toward improving patient compliance levels 
and outcomes (Castro et al., 2006).
Souza and Bertoncin (2008) followed and provided 
weekly counseling to 10 hypertensive adult volunteers for 
2 months in Pouso Alegre, Minas Gerais State, to evaluate 
blood pressure levels, motivate patients on correctly use 
of medicines, and to improve levels of compliance with 
treatment. This study suggested that pharmaceutical home 
care is important for monitoring hypertensive patients and 
motivating patients to improve compliance with therapy.
Sixty-four diabetic patients who were being treated 
at a Public Healthcare Center in Ribeirão Preto, São Paulo 
State, Southeast of Brazil, were followed by pharmacists. 
At the end of a 9-month follow-up period reductions 
were seen in the values of glycated hemoglobin (2.15%), 
fasting glycemia level (8.91%), systolic blood pressure 
level (3.55%), and diastolic blood pressure level (1.85%) 
compared to initial values on biochemical tests (Ferreira 
et al., 2006).
Despite the encouraging evidence, implementing 
compliance-enhancing strategies through pharmacist 
interventions on a large scale is quite challenging due to 
the total costs involved, lack of user-friendly tools, need 
for training of healthcare professionals, and difficulties in 
program implementation (Svarstad et al., 2009).
CONCLUSION
Compliance with treatment is a complex and chal-
lenging issue for healthcare professionals and patients. It 
is well known that the effectiveness of pharmacotherapy 
depends on an agreement between patients and healthcare 
providers. In the event that this agreement proves im-
possible for whatever reason, society faces an important 
problem which frequently results in increased healthcare 
costs and rising demand for human resources.
Over recent years, many studies have shown the 
impact of pharmacist intervention on improving complian-
ce levels and patient outcomes, especially for treatment 
of chronic diseases. The greatest challenge today is the 
successful implementation of compliance-enhancing 
strategies for large populations.
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